Investor mix
8 investors on record; lead investors include F-Prime Capital, Atlas Venture.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 7 | 88% |
| Other / undisclosed | 1 | 13% |
Developing small molecules targeting RGD-binding integrins to treat fibrotic diseases
8 investors on record; lead investors include F-Prime Capital, Atlas Venture.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 7 | 88% |
| Other / undisclosed | 1 | 13% |